Endocrine Abstracts

Introduction: There is growing real-world experience of the SGLT2 inhibitor class for type 2 diabetes mellitus (T2D). We performed an audit of clinico-biochemical effects of SGLT2 inhibitor use for patients with diabesity in the context of a tier-3 obesity service within a UK-based teaching hospital.

Methods: We included patients with a confirmed diagnosis of T2D who had been treated with an SGLT2 inhibitor within licensed indications (monotherapy and addition to oral and insulin therapies) for at least 3 months. We ascertained changes in HbA1C and body weight on SGLT2 inhibitor (mean and standard deviation [S.D.]).

Results: Thirty-two patients were included (dapagliflozin [n=13], canagliflozin [n=5] and empagliflozin [n=14]). Mean baseline HbA1C and body weight were 79.3 mmol/mol and 110.1 kg respectively. At 3-months following SGLT2 inhibitor initiation, HbA1c reduced by 10.0 mmol/mol [S.D.=11.2], and body weight by 3.3 kg [S.D.=3.6]. At 6-months, HbA1c reduced by 16.5 mmol/mol [S.D.=11.7] and body weight by 5.4 kg [S.D.=7.2]. One patient had a 20% reduction of body weight at 6-months with an SGLT2-inhibitor agent and some patients (n=9) had HbA1c reduction of >20%.

Conclusion: Our real-world evidence confirms that SGLT2 inhibitors in patients with T2D and obesity in the context of a tier-3 obesity service are efficacious, with reductions in both HbA1C and body weight being comparable to RCT data for these agents. Our data also suggest that some patients are ‘super’-responders to SGLT2-inhibitors: future studies should identify further predictors of response.